Document and Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Apr. 30, 2025 |
Jul. 17, 2025 |
Oct. 31, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Entity Central Index Key | 0001877184 | ||
| Amendment Flag | false | ||
| Current Fiscal Year End Date | --04-30 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Apr. 30, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Entity File Number | 001-42549 | ||
| Entity Registrant Name | Kestra Medical Technologies, Ltd. | ||
| Entity Incorporation, State or Country Code | D0 | ||
| Entity Address, Address Line One | 3933 Lake Washington Blvd NE | ||
| Entity Address, Address Line Two | Suite 200 | ||
| Entity Address, City or Town | Kirkland | ||
| Entity Address, State or Province | WA | ||
| Entity Tax Identification Number | 00-0000000 | ||
| Entity Address, Postal Zip Code | 98033 | ||
| City Area Code | 425 | ||
| Local Phone Number | 279-8002 | ||
| Title of 12(b) Security | Common Shares, par value $1.00 per share | ||
| Trading Symbol | KMTS | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE The information required by Part III of this Annual Report, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting to be held in 2025, which definitive proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates (the “Proxy Statement”). |
||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 0 | ||
| Entity Common Stock, Shares Outstanding | 51,348,656 | ||
| Auditor Firm ID | 238 | ||
| Auditor Name | PricewaterhouseCoopers LLP | ||
| Auditor Location | Irvine, California | ||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Kestra Medical Technologies, Ltd. and its subsidiaries (the “Company”) as of April 30, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of changes in redeemable preferred stock and shareholders’ equity (deficit) and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. |